Advanced searches left 3/3

Latanoprost ophthalmic - DOAJ

Summarized by Plex Scholar
Last Updated: 11 July 2022

* If you want to update the article please login/register

Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma

OBJECTIVES: Timolol maleate has been shown to be a safer intraocular pressure lowering therapy than latanoprost. METHODS: Patients who received latanoprost eye drops every day in the evening were included in the latanoprost Ophthalmic Solutions cohort. Those who received latanoprostene bunod eye drops every evening in the evening were included in the Latanoprostene Bunod group. Those who got timolol eye drops twice a day were included in the Timolol Maleate group. Compared to the LP and TM cohorts, the LB cohort had the highest IOP reduction in IOP.

Source link: https://doi.org/10.6061/clinics/2020/e1874


An Evaluation of the Physicochemical Properties of Preservative-Free 0.005% ( w / v ) Latanoprost Ophthalmic Solutions, and the Impact on In Vitro Human Conjunctival Goblet Cell Survival

Xaloptic Xaloped Free; five preservative-free 0. 005% latanoprost ophthalmic drugs; Monoprost 00ae; Latanest 00ae; Gaap;, Whatt, Xaloptic 00ae (u00ae) and Xalopetic 00ae Free; Xaloptic 00ae Free; five preservative-free 0. 005 In addition, the research investigated the mucin production and cell survival of primary cultured human conjunctival goblet cells treated with PF eye drops. Monoprost u00ae had a pH value nearest to that of tear fluid's pH value, whereas Gaap Oftenou00ae and Latanest u00ae had the lowest pH values, with Monoprost u00ae having the lowest pH values. Between the treatments and control, no significant differences were observed in goblet cell survival or mucin release.

Source link: https://doi.org/10.3390/jcm11113137


Maximization of the in vitro transcorneal release and the in vivo IOP-lowering effects of Latanoprost ophthalmic gel formulations using Azone as a penetration enhancer and Carbopol-974® as a mucoadhesive.

The in vitro transcorneal release of LAT from a first batch of gel formulations with different amounts of Azone at a set concentration of C-974. u00ae was investigated. For the manufacture of a second series of ocular gels with different C-974u00ae concentrations, the formulation that showed the highest permeability at the lowest Azone concentration was chosen. In vivo IOPlowering efficacy testing for the scaled-up formulations from both sets of the test formulations was conducted in rabbits for four days in a row. According to the developers, GAZ-4 and GC-4 had the highest IOP reduction results, with 7. 8 mmHg and 6. 5 mm Hg as respectively. Both gel formulations were extended and extended for up to two days, according to the report that the in vitro release, onset, presence, and duration of action of the LAT gels had been extended and prolonged for up to two days.

Source link: https://doaj.org/article/f0c2bd86e8314400a3800da4d43c9b75


Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma

Introduction: Benzalkonium chloride, a preservative in several topical therapies for glaucoma, has been used by the Western Regional Institute of Ophthalmology, Civil Hospital, Ahmedabad, 4Clinical Research Department, Sun Pharma Advanced Research Company Ltd. , Mumbai, India, 3Glaucoma Clinic, M and J, causes significant injury and alters tear breakup times. BAK-containing latanoprost, an ester prodrug of prostaglandin F2a's ester prodrug, may cause ocular adverse events associated with BAK. Patients with primary open-angle glaucoma or ocular hypertension receiving BAK-containing latanoprost for &ge were assessed and evaluated for &ge for 8 months. Patients were referred to BAK-free latanoprost ophthalmic gel 0. 005 once a day, and eyes were monitored after 28 and 56 days. Mean TBUT transformed from baseline to 5. 03 million men;2. 64 and 6. 06±3. 39 seconds after 28 and 56 days of BAK-free latanoprost therapy. Compared to baseline, the Ocular Surface Disease Index© score also dropped significantly to 12. 40 and 7. 06 million, respectively; 10. 75 at 28 and 56 days; respectively; compared to baseline; At both time points, there was a decrease in conjunctival hyperemia and intraocular pressure. In seven patients, no treatment-related serious AEs were present, while 12 treatment-emergent AEs were reported, with eye pain and irritation being the most frequent. Conclusion: The change from BAK-containing latanoprost to BAK-free latanoprost resulted in significant improvements in TBUT, OSDI© score, and poor corneal staining score, as well as concrete decreases in conctival hyperemia scores, according to the results. This helpful feature appears to be effective in shielding ocular surface integrity in glaucoma patients using BAK-free latanoprost, but further research is required to confirm this beneficial effect.

Source link: https://doaj.org/article/8d5799b8d5864060a340f146b499aef2


Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review

F2-alpha isopropyl ester prodrug that is quickly hydrolyzed by esterases in the cornea to the biochemically active latanoprost acid, a novelist Latanoprost. The cornea appears to be behaving like a slow-release depot to the anterior segment when latanoprost is topically applied to the eye. Maximum concentrations are discovered in the iris one hour after the administration, followed by the anterior chamber and the ciliary body. The intraocular pressure reduction with topical prostaglandin F2-alpha has been associated with a decrease of collagens within the uveoscleral outflow pathway, according to immunohistochemical studies. Latanoprost is a valuable addition to several experimental and scientific studies demonstrating that it is one of the most effective treatment options for glaucoma, ocular hypertension, and even angle-closure glaucoma.

Source link: https://doaj.org/article/4ff5fad9208f4d4dac68f95d5b98d64c

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions